U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

the FDA is closely monitoring the marketplace and is committed to taking action, as appropriate, to best protect public health." Senator Chuck Schumer, at a press conference in June 2024 ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

The approval was announced in an FDA press release, and it will be sold under the brand name Journavx by Vertex Pharmaceuticals. This painkiller's approval reflects the FDA’s commitment to ...

SMi Group Reports: Following the FDA’s release of a ... [centerforbiosimilars.com] Also in recent news were statements made by the chair of this year’s two-day conference; Richard DiCicco ...

GRAFAPEX for injection holds Orphan Drug Designation, according to the press release, which means that the product will benefit from a seven- year period of regulatory exclusivity in the FDA-approved ...

director of the Office of Science in the FDA Center for Tobacco Products, said in an agency news release. “In this case, the data show that these nicotine pouch products meet that bar by ...

The Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) with Priority Review for RP1 (vusolimogene oderparepvec) in combination with Opdivo (nivolumab) for patients ...

The strategy, the FDA said, is informed by science and aims to spread knowledge across the industry about how to detect enteric viruses. “Over many years, outbreaks of enteric virus infections ...